2022 World Conference on Lung Cancer (ePosters)-EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC

EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC

Back to course

Pdf Summary

This research study aimed to investigate the real-world immune-mediated adverse events (imAEs) and treatment interruptions/discontinuations associated with durvalumab, a standard of care treatment for patients with unresectable stage III NSCLC. The study was conducted using a retrospective cohort of patients treated with durvalumab at the Veterans Health Administration.<br /><br />The findings of the study indicated that patients who experienced imAEs were at a higher risk of having a treatment interruption with durvalumab. Additionally, patients who developed pneumonitis, a common adverse event, were at a higher risk of treatment discontinuation and had a shorter duration of therapy compared to those without pneumonitis.<br /><br />These findings highlight the importance of early identification and management of imAEs in patients receiving durvalumab. By identifying and managing these adverse events earlier, clinicians may be able to reduce treatment interruptions and discontinuations, allowing patients to receive the full benefit of durvalumab.<br /><br />The study included 935 patients who met the study criteria, with a predominantly older and male population. The majority of patients completed 12 months of durvalumab treatment. Adverse events and imAEs were reported more frequently in patients who experienced treatment interruptions, while imAEs were more common in patients who discontinued therapy. However, the difference in imAEs between patients who discontinued therapy and those who completed therapy was no longer significant when adjusted for other factors.<br /><br />Overall, this study provides valuable insights into the impact of imAEs and treatment interruptions on patients receiving durvalumab for unresectable stage III NSCLC. It emphasizes the need for healthcare providers to be vigilant in recognizing and managing these adverse events to optimize patient outcomes. Further research and clinical interventions may be necessary to improve the management and overall experience of patients receiving durvalumab.

Asset Subtitle

Amanda M Moore

Meta Tag

Speaker Amanda M Moore

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

immune-mediated adverse events

treatment interruptions

treatment discontinuations

durvalumab

unresectable stage III NSCLC

retrospective cohort

pneumonitis

early identification

management

clinicians